Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

24.01 +0.76 (+3.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
A Peek at Sarepta Therapeutics's Future Earnings
 
Via Benzinga
Tradr Unleashes 2X Single-Stock Gold ETFs, Reshaping Short-Term Gold Investment Landscape
New York, NY – October 23, 2025 – Tradr, a prominent innovator in the Exchange-Traded Fund (ETF) market, has today significantly expanded its product suite with the launch of nine new single-stock 2X... 
Via MarketMinute
Topics Artificial Intelligence Derivatives ETFs
Tradr Launches 9 Single-Stock 2X ETFs With First-Of-Its-Kind OpenDoor, Gold And AI Exposure
The new ETFs include the first-of-their-kind gold and AI plays, giving traders targeted exposure without using margin or complex options. 
Via Benzinga
Topics Artificial Intelligence ETFs
This Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees Opportunity
Via Stocktwits
Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF
Funds seek to provide 200% long exposure on a variety of industry leaders 
Via Stocktwits
Topics ETFs
What's Going On Sarepta Stock On Wednesday?
Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week. 
Via Benzinga
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket
Investors turned upbeat ahead of Sarepta’s data presentations in Vienna, where the company is expected to share new Duchenne muscular dystrophy results and updates from its broader gene therapy... 
Via Stocktwits
Topics Death
Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant... 
Via MarketMinute
Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday. 
Via Benzinga
Topics Stocks
Incannex Healthcare (NASDAQ: IXHL) Braces for Volatility as Q4 Earnings Loom: Options Traders Eye Strategic Plays
Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29,... 
Via MarketMinute
Topics Artificial Intelligence Earnings
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 43 Analysts
 
Via Benzinga
2 Beaten-Down Stocks to Avoid Right Now
These once high-flying stocks no longer seem to have promising prospects. 
Via The Motley Fool
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Forecasting The Future: 44 Analyst Projections For Sarepta Therapeutics
 
Via Benzinga
Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why
Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal. 
Via Stocktwits
What's Going On With Sarepta Shares Thursday?
 
Via Benzinga
Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients
The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 
Via Stocktwits
Topics Death
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday. 
Via Stocktwits
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company. 
Via Investor's Business Daily
Topics Death
Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial
Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025. 
Via Stocktwits
How Do Investors Really Feel About Sarepta Therapeutics?
 
Via Benzinga
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
Per two Wall Street analysts, one of 2025's biggest losers could be set up for a stunning recovery. They see over 175% upside in Sarepta Therapeutics. 
Via MarketBeat
Topics Death
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
C3.ai, Destiny Tech100 And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Trump Ally Laura Loomer Calls Vinay Prasad A ‘Marxist Trojan Horse’ After FDA Rehiring, Slams NASA For Dropping Isaacman
Prasad resigned from the FDA in July after backlash over his handling of Sarepta’s Elevidys gene therapy, which faced shipment restrictions following patient deaths before being partially reinstated. 
Via Stocktwits
Topics Death Government
What 43 Analyst Ratings Have To Say About Sarepta Therapeutics
 
Via Benzinga
Dow Futures Rise As Trump’s Reciprocal Tariff Deadline Kicks In: AAPL, NVDA, INTC, LLY, SRPT Among Stocks To Watch
Via Stocktwits
Topics Government Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.